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Abstract: Depression and anxiety are prevalent in children with rheumatologic diseases, includ-
ing juvenile idiopathic arthritis (JIA). However, prevalence rates and the relationship with disease
outcomes, including quality of life are conflicting in the early literature. To review the current
literature, determine gaps in our knowledge, and identify areas in need of further investigation, we
conducted a systematic review of studies examining depression and anxiety symptoms among
childrenwith JIA and the impact these symptomsmay have on disease outcomes and quality of life.
Six electronic databases were searched up until January 2019. Of 799 potential articles, 60 articles
were included with the main focus on 28 articles from 2009 to 2019, to concentrate on the most
current evidence. We found that JIA patients experience symptoms of depression and anxiety
similar to other childhood chronic diseases and at higher rates than in healthy children. Patients
who experience these symptoms have worse quality of life, with some evidence pointing to
depression and anxiety symptoms having a greater impact on quality of life than other disease
features, such as active joint count. Family members of JIA patients experience high rates of
anxiety and depression symptomswhichmay impact their child’smental health and pain symptoms
related to JIA. Conflicting reports of associations between depression/anxiety symptoms and
disease features/disease outcomes and a paucity of longitudinal studies investigating the impact
of treatment on mental health symptoms indicate areas in need of further research to effectively
identify patients at greatest risk of depression and anxiety and to better understand how to treat and
prevent these symptoms in youth with JIA. Family mental health should also be considered in
investigations concerning mental health and disease outcomes of children with JIA.
Keywords: pediatric rheumatology, mental health, mood disorder, arthritis, autoimmune
disease
Introduction
Juvenile idiopathic arthritis (JIA), diagnosed in children under 16, affects an
estimated 1.7 to 8.4 million children worldwide.1 Incidence rates are estimated to
be around 1.6–23 per 100,000.2 All races, ethnicities, and ages can be affected.
However, females tend to be more frequently affected than males. Children with
any of the six different classifications of JIA: oligoarticular (<5 joints), polyarti-
cular (>4 joints), systemic, psoriatic, enthesitis-related (ERA), and undifferentiated
can experience musculoskeletal pain and disability, fatigue, and symptoms of
psychological distress such as depression and anxiety.
Currently, the incidence of mental health disorders is on the rise within the
general United States (US) population. The National Survey on Drug Use and
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Health (NSDUH) found that from 2011 to 2016 the pre-
valence of depression in adolescents increased from 8.3%
to 12.9%.3 Children who suffer from chronic disease have
higher rates of anxiety and depression than the general
population.4–6 In addition, children with chronic disease
have less favorable courses regarding their mental health
symptoms over time.7
Reviews of the earlier literature on mental health in
children with juvenile arthritis indicated that symptoms of
depression and anxiety are prevalent in this population and
established the inter-connectedness of parental and child
mental health in families affected by JIA.8–10 However,
studies have reported a wide range of rates for both symp-
toms and diagnoses of mental health disorders and have
conflicted regarding the relationship between these symp-
toms, disease features, and disease outcomes. Many were
limited by small sample sizes, with some studies including
fewer than 30 patients,11–13 few included significant pro-
portions of racial and ethnic minorities, and few were
conducted outside the US and Europe.8 Many studies
examined children with JIA as part of a general cohort
of children with other rheumatologic diseases,11,14–18
restricting our understanding of the relationship of psycho-
logical symptoms to disease-specific outcomes. In the
interim, our treatments and even our classifications of
chronic juvenile inflammatory arthritis have changed.
The past decade of research in pediatric rheumatology
has benefited from the development of longitudinal
cohorts (institutional, multicenter, and even international)
of both children and adults who suffer from diseases such
as JIA.19–21 These studies have enhanced our understand-
ing of the epidemiology, risk factors, and outcomes asso-
ciated with rheumatologic diseases. Given the changes in
the field and the general rising prevalence of mental health
disorders, we aimed to conduct a systematic review of the
recent literature of depression and anxiety in JIA to sum-
marize our knowledge to date, determine gaps in our
understanding of depression and anxiety in this population,
and identify areas in need of further investigation that will
improve care of youth with JIA.
Methods
Eligibility Criteria
Studies were included in the review if they (1) involved
children, adolescents, and/or adults with JIA, (2) focused
on depression and/or anxiety symptoms, and (3) were an
original, primary source of research available in English.
Data Sources
The following databases were searched to identify relevant
studies for this systematic review: Ovid MEDLINE,
PsycINFO, Web of Science Core Collection, Scopus, the
Cumulative Index of Nursing and Allied Health Literature
(CINAHL), and Cochrane Database of Systematic
Reviews and Cochrane Register of Controlled Trials. The
search included literature up until January 2019 and was
conducted by a medical librarian in February 2019.
Search Strategy And Study Selection
The published literature was searched using strategies
designed by a medical librarian for the concepts of juve-
nile idiopathic arthritis or juvenile rheumatoid arthritis and
depression or anxiety. Search terms related to juvenile
rheumatoid arthritis included the MeSH term “arthritis,
juvenile” and keywords related to childhood, childhood-
onset or juvenile combined with terms for arthritis includ-
ing arthrosis, rheumatism, and Still’s disease. Search terms
related to mental health included the MeSH terms “depres-
sion”, “depressive disorder, major”, “anxiety” and “anxi-
ety disorder”, and keywords such as depressive, depressed,
anxious, or anxiety.
The initial search was done in Ovid MEDLINE, and
the search strategy was peer reviewed by another librar-
ian prior to being translated into subsequent databases.
A total of 799 unique references were found. A flow-
chart of the study identification process is provided in
Figure 1. Whereas, full search strategies are provided in
the supplementary appendix Table S1.
The remaining 799 articles were organized in Rayyan
Qatar Computing Research Institute (QCRI), a web-based
app for systematic reviews.22 All decisions for study inclu-
sions and exclusions were taken by consensus based on how
well the study fit the inclusion criteria. Each abstract was
screened by two of three authors (D.F., M.R., and T.R.) in a
blinded fashion. Discrepancies were resolved by the third
author who had not yet screened the article. This led to a total
of 158 articles for potential inclusion in the review. Finally,
the full texts of all the potentially included articles were
independently reviewed by three authors (D.F., M.R., and
T.R.) to determine the final selection of articles. All initially
included articles were reviewed, but focus was placed on
those written from 2009 to 2019 in order to concentrate on
the most current evidence. Full-text articles were excluded
for the following reasons: (1) a duplicate article missed in the
initial screening, (2) an article was found to be unavailable in
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the English language, (3) there was no assessment of anxiety
and/or depression in JIA patients, (4) an article did not
analyze JIA separately from the rest of the study population,
(5) a poster abstract and not a full manuscript, and/or (6) an
article was not original research. At the conclusion of the
search and screening process, 60 articles were selected for
inclusion of which 28 articles were written between 2009 and
2019.
Data Extraction
The data extracted from the final articles included the
title, author(s), year of publication, country in which the
study was conducted, patient characteristics (age, gender,
sample size, race, ethnicity, disease(s), subtype of JIA,
disease duration, disease activity, and medication(s)),
family socioeconomic characteristics (parent’s educa-
tional level and family income), and findings related to
depression and anxiety. Reviewers recorded the assess-
ments that were used to screen for anxiety and/or depres-
sion and measure the quality of life in both patients and
families along with the measures of JIA disease charac-
teristics such as disease activity, mobility, pain, and glo-
bal health scores. Lastly, reasons for exclusions and
limitations were included as well.
Figure 1 Flowchart of selection process for study inclusion in the systematic review.
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Results
Study Characteristics
Overall, 28 articles from 2009 to 2019 were included
(Table 1): three-fourths addressed the prevalence of
depression, half addressed the prevalence of anxiety, and
fewer than one-third addressed the relationship of mental
health to JIA disease characteristics or the impact of men-
tal health on patient quality of life. Of the 28 current
articles, 24 were conducted in countries outside of the
US, including countries outside of North America and
Europe (Iran, Turkey, and Egypt).
Population Characteristics
Twenty-five articles included youth with JIA while 3 arti-
cles studied adults. Four studies compared JIA to other
chronic childhood diseases. As expected based on the
general demographic patterns associated with JIA, study
populations included a majority of female patients (range
52–81%) with the exception of one study.23 Among the
included pediatric studies, the mean age was 6.9 to 15.5
years and the age range in the adult studies was 18 to 73
years. Most studies did not report race and/or ethnicities.
In the 6 studies that did report race, ≥70% of the subjects
were Caucasian or white.24–29 JIA disease duration ranged
between 3 months to 15 years in children and 10 to 27
years in adults.24–28,30-44
JIA subtype was described in 14 studies: 13 included
polyarticular,24–26,30,31,35–40,45,46 11 included oligoarticu-
lar,24,26,30,31,35–40,46 10 included systemic,25,26,30,31,35–40 and
fewer included ERA, psoriatic, undifferentiated, spondyloar-
thropathy, and other forms of arthritis.25,26,30,31,34–37,40,46 JIA
subtypes were described by all 3 of the adult studies.42–44
Mental Health Measures
Recent studies mostly relied on patient-reported symptom
scales, though parent-reported tools were often used in
conjunction (Table 2). Depression was evaluated by a
variety of questionnaires, most commonly the Children’s
Depression Inventory (CDI; in 9/22 depression studies).
Other measures used were the Mood and Feelings
Questionnaire (MFQ), Beck Depression Inventory-2
(BDI-II), and the Center for Epidemiological Studies
Depression Scale for Children (CES-DC). Anxiety was
evaluated most commonly by the Screen for Child
Anxiety Related Disorders (SCARED; in 3/14 anxiety
studies). Other anxiety measures used were the State
Trait Anxiety Inventory (STAI), Anxiety Checklist for
Children and Adolescents, and the Self-Administered
Psychiatric Scales for Children and Adolescents-Anxiety
questionnaire (SAFA-A). To assess symptoms of either
depression or anxiety, the Achenbach Child Behavioral
Checklist (CBCL), Mini-International Neuropsychiatric
Interview for Children (MINI-KID), Schedule for
Affective Disorders and Schizophrenia for School-Age
Children-Present and Lifetime Version (KSADS-PL),
self-report, and psychiatric interviews were used.
Prevalence Of Depressive Symptoms In
JIA
Most studies that used validated screens for depressive
symptoms reported prevalences of clinically significant
symptoms in the range of 7–36% in children with
JIA.23–26,28,29,35,38,39,41,46,47 Reda et al used the MINI-
KID psychiatric interview and reported that 93% of the
patients had dysthymic disorder while 3% had major
depressive disorder.30 El Najjar et al found that all JIA
patients scored above the cut-off for clinically signifi-
cant symptoms on the CES-DC questionnaire.37 There
were 4 studies that reported no clinically
significant depressive symptoms within their study
population.27,31–33 These studies all used the CDI or
BDI, screens that were used to detect prevalence rates
of clinically significant symptoms in other studies from
9% to 36%,24,25,39 but were notable for patient popula-
tions from reportedly high socioeconomic levels27,33
and/or restricted to either non-acute patients32,33 or
patients without comorbid psychiatric diagnoses.31
Three studies compared JIA patients to healthy con-
trols, of which two found that JIA patients had worse
depressive symptoms.23,35 Two additional studies reported
that youth with JIA had worse anxiety/depressive symp-
toms than healthy controls; however, these symptoms were
not analyzed separately.41,48 The exception, Tarakci et al,
did not find a significant difference between JIA patients
and healthy controls in regards to depression and/or anxi-
ety symptoms; however, they excluded JIA patients with
known comorbid psychiatric diagnoses.31 Notably, Kayan
Ockagoglu et al reported that 28% of their JIA cohort had
a known diagnosis of major depressive disorder.23
From the 3 studies that evaluated adults with JIA, two
noted a particularly high prevalence of either depression or
anxiety symptoms. Barth et al found significantly higher
rates of anxiety/depression in JIA adults (18% in men,
37% in women) compared to healthy adults, and Rebane
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et al reported a depression prevalence of 34%.43,44 In
contrast, Raab et al found that only 4.9% of the adults
with JIA self-reported depression, significantly fewer com-
pared to the general population.42
While most studies reviewed did not analyze a differ-
ential prevalence of depressive symptoms based on age or
gender, those that did agree with trends in the general
population with older adolescents and females showing
worse scores.37,46,49
Prevalence Of Anxiety Symptoms In JIA
The prevalence of clinically significant symptoms
of anxiety in youth with JIA ranged from 7% to
64%.23,25,28,29,35,41,47,50 While most studies reported
higher rates of depression than anxiety, a few notable
studies found the opposite.29,35,47 Most studies com-
paring to healthy controls found higher rates among
youth with JIA.35,41,47 Kayan Ocakoglu et al found
that JIA patients scored worse on the SCARED and
were more likely to have diagnoses of anxiety disor-
ders compared to healthy controls, but the difference
did not reach statistical significance, likely due to a
small sample size.23 Tarakci et al, another exception,
had a cohort of JIA patients that excluded those with
comorbid psychiatric disease.31 Bomba et al looked at
specific subscales for different types of anxiety (gen-
eralized, social, separation, and school anxiety) and
found that with each, youth with JIA scored worse
than controls.35
Butler et al was the only longitudinal study reviewed
that examined anxiety and theirs was a pilot study of
children with multiple chronic diseases, including a very
small number of JIA patients. They found both overall and
in JIA patients, high rates of anxiety (up to 36%) at base-
line and 6-month measurements.29
Few studies analyzed the prevalence of anxiety symp-
toms by age or gender. Russo et al found that children
with JIA, ages 6–10 years, scored slightly higher on an
anxiety questionnaire than adolescents with JIA, but this
finding was not statistically significant. They also noted
that psychological unease was reported in all JIA chil-
dren, ages 6–10 years, compared to 42% of the
adolescents.32 Raab et al was the only study to evaluate
anxiety in adult patients with JIA and reported that 2% of
the adults with JIA self-reported anxiety disorders in a
comorbidity questionnaire.42T
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Pathophysiology Of Mental Health In JIA
In 2011, Capuron et al found an association between
chronic low-grade inflammation in elderly individuals
with altered neurotransmitter metabolism and disturbed
mental well-being.51 Then, in 2018, a review was pub-
lished discussing the association between inflammation in
rheumatoid arthritis and depression.52 Therefore, Korte-
Bouws et al decided to evaluate this relationship in JIA
by measuring serum samples of a panel of neurotransmit-
ters in children with active JIA. They discovered that
ratios between specific neurotransmitters indicated likely
elevated activity of enzymes in dopamine and serotonin
pathways. This may explain a pathway between active
inflammation in JIA and symptoms of depression, anxiety,
fatigue, and even cognitive impairment.53
Reda et al found that the patterns of cerebral perfusion
deficit in patients with JIA are similar to perfusion patterns
observed in patients with diagnosed depression and/or
anxiety. With single-photon emission computed tomogra-
phy (SPECT) imaging, they found that children with JIA
had a significant decrease in perfusion of the right frontal
and right parietal lobes and a significant increase in perfu-
sion of the left parietal and left occipital lobes when
compared to healthy controls. These regions of the brain
are known to be involved with mood regulation, attention
span, and anxiety.30
Risk Factors For Depression And Anxiety
In Youth With JIA
Patient Characteristics
Hanns et al found that polyarticular patients scored sig-
nificantly higher than oligoarticular and ERA patients on
depressive symptoms. There was no difference in scores
for depressive symptoms between the oligoarticular and
ERA patients.46 Conversely, El-Najjar et al did not find
any statistically significant difference between the depres-
sive scores of polyarticular, oligoarticular, systemic, and
ERA subtypes. However, all patients scored above the
clinically significant cut off for depressive symptoms by
the CES-DC.37
Disease Activity
Many of the articles found a correlation between disease
activity markers and depression symptoms. Specifically,
Hanns et al noted that both a higher active joint count
and higher limited joint count correlated with higher
depressive scores in the first year, but this relationship
was no longer significant after follow up four years later.46
Similarly, another study found a statistically significant
correlation between depression scores and physician glo-
bal scores, number of tender joints, number of swollen
joints, number of limited joints, and the Juvenile
Arthritis Disease Activity Score (JADAS-27).37 In Barth
et al’s study of adult JIA patients, they found that anxiety/
depression symptoms on a health-related quality of life
questionnaire were significantly worse in patients with
active versus inactive disease. Active disease in this
study was also associated with worse mobility, self-care,
usual activities, and pain/discomfort.43 Conversely,
Tarakci et al did not find any significant correlation
between depression or anxiety and total active joint
count.31
Two studies evaluated the relationship between disease
duration and anxiety or depression with opposing findings
regarding a correlation between duration and symptoms.
El-Najjar et al found a strong correlation between worse
depression symptoms by CES-DC,37 while Tarakci et al
found no correlation between disease duration and the
CDI.31 In part, this may be due to the differing populations
of JIA subtypes in these two studies (28% vs 52% poly-
articular, respectively).
Disease Burden
Three studies found a statistically significant relationship
between the Childhood Health Assessment Questionnaire
(CHAQ), a patient-reported outcome of physical function,
and depression scores.31,37,46 Additionally, Hanns et al
found that a higher baseline depression score predicted
worse disability in patients one and four years later.46 On
the other hand, Tarakci et al did not find a significant
relationship between functional ability level, as measured
by physical activities and energy expenditure, and anxiety
or depression.31
Though most studies supported an association between
active disease and worse mental health symptoms, mana-
ging disease with medications and blood test monitoring
can be a source of psychological burden, as well. Mulligan
et al assessed anxiety specific to injections and blood tests
in children with JIA on methotrexate for ≥6 months. Over
half reported feeling anxious about either. Anxiety about
injections was associated with younger age, higher current
disease activity, and subcutaneous administration, while
anxiety about blood tests was significantly related to a
younger age and a shorter duration of time on methotrexate.
Importantly, blood test anxiety was an independent predic-
tor for poorer scores in psychosocial quality of life.36 Barth
Dovepress Fair et al
Open Access Rheumatology: Research and Reviews 2019:11 submit your manuscript | www.dovepress.com
DovePress
245
et al’s study of adults found an association between treat-
ment for JIA as an adult and overall lower quality of life.43
Notably, treatment for JIA in adulthood may be a marker
for progressive, more severe disease.
Pain
Many studies evaluated the relationship between mental
health symptoms and pain and most found an association
between pain and either symptoms of anxiety or
depression.24,37,46,50 The experience of pain may be influ-
enced by particular stress-coping strategies reflective of a
child or adolescent’s level of anxiety.50 Hanns et al noted
that a higher baseline depression score predicted worse
pain at one and four years later.46 Bromberg et al found
that daily reported mood was associated with daily mea-
sures of pain.45 Tarakci et al was the outlier, finding no
significant correlation between pain and depression or
anxiety.31
Impact On Quality Of Life
Throughout the literature, depression symptoms consis-
tently correlated with impaired overall quality of
life.31,34,35,39 Abdul-Sattar et al found that over three-
fourths of patients with significant depression symp-
toms had poor quality of life.39 As expected, studies
found that depression symptoms inversely correlated to
emotional and social function on measures of quality of
life.35 Proxy parent reports of symptoms of their chil-
dren’s depression significantly predicted worse quality
of life.34
Anxiety also appears linked to quality of life in the
reviewed literature. Children with JIA with a negative
perception of their own life have higher anxiety scores.34
However, Stevanovic et al found that after accounting for
disease features, pain, and demographics, the association
between anxiety and quality of life was lost.35
A few studies looked specifically at quality of sleep
and school functioning as markers of quality of life. Hrelic
et al found that 80% of the children with JIA reported
sleep disturbances of which night waking and parasomnias
were significantly correlated with both anxiety and depres-
sion symptoms.28 Bromberg et al reported that mood
moderated the relationship between quality of sleep and
pain.45 Higher depression scores are strongly associated
with poorer school functioning and school absenteeism in
youth with JIA. Among JIA patients with significant
depression, 88% had school absences and 69% had poor
school functioning.38
A study of adults with JIA evaluated patients on
whether they were socially restricted versus non-restricted.
The restricted patients were unemployed or on disability
while the non-restricted were studying, working, on mater-
nity leave, or in the military. They found that 83% of the
patients were socially non-restricted compared to 16%
restricted. Of the 16% that were restricted, the majority
(85%) were unemployed. The socially restricted JIA
patients spent less time in leisure non-physical activities,
felt more disturbed during leisure time, had lower self-
esteem scores, and higher disability scores. They also had
statistically significant lower health-related quality of life
scores in physical and social functioning as well as emo-
tional well-being compared to the non-restricted.
However, they did not find any difference between the
depressive scores between the two groups. Of note, 59%
of the restricted patients had polyarticular JIA compared to
47% of the non-restricted patients; therefore, it could be
hypothesized that some differences between the two
groups were secondary to worse disease activity in the
restricted patients. In contrast, there was no statistically
significant difference in disease duration between the two
groups.44
Impact On Parents And Family
A few studies addressed the mental health of caregivers of
children with JIA. Vuorimaa et al found that 12% of the
caregivers had clinically significant depressive symptoms
while 7% had anxiety. Children’s pain was significantly
associated with their parents’ depressive symptoms and
children’s depressive and anxiety symptoms moderately
correlated with those of their parents.24 Russo et al found
that 17% of the mothers of children with JIA and a third of
their siblings sought psychological support, while a quarter
of mothers endorsed being on an anti-depressant.32
Through a health-related quality of life questionnaire, par-
ents of children with active disease scored significantly
worse in depressive symptoms than the parents of children
with inactive disease.40
Haverman et al report that parents of children with JIA
perceived their child as more vulnerable compared to
parents of healthy children and parents of children with
other chronic diseases.40 Anthony et al found that higher
parent perception of child vulnerability correlated with
child depressive symptoms, and children perceived as
more vulnerable were also more anxious. In addition,
parent daily stress, specifically more intense daily hassles
and fewer daily uplifts, predicted higher depressive
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symptoms in their children with JIA. They concluded that
children of parents with more daily stress and less stress
relief were more susceptible to depressive symptoms, and
that parent experiences of daily uplifts or pleasurable
events may be protective to the development of depressive
symptoms in their children with JIA.25 In contrast to the
psychopathology described among JIA caregivers in these
studies, Graziano et al found that with regards to emo-
tional complaints and psychosocial distress, JIA mothers
appeared to have more in common with mothers of healthy
controls than with mothers of cancer patients.48
Comparison Of Mental Health In JIA And
Other Chronic Diseases
Four articles analyzed mental health in JIA compared to
other chronic childhood diseases including inflammatory
bowel disease (IBD), primary immunodeficiencies (PIDs),
and cancer.23,33,47,48 Overall, JIA patients had similar
depression/anxiety symptom levels compared to the other
chronic diseases, with the exception of IBD patients who
were found to be more depressed.33 Kayan Ocakoglu et al
had children evaluated through a psychiatric interview and
found that 63% of the JIA children, 70% of the PIDs, and
23% of the healthy children had some form of a psychia-
tric disorder (this included disorders other than mood and
anxiety such as psychotic, elimination, disruptive, sub-
stance abuse, eating disorders, and tic disorders).23
Discussion
Studies of depression and anxiety in youth with JIA con-
ducted in the last 10 years reported that between 7% and
64% of the JIA patients have symptoms of anxiety or
depression. These prevalence rates are at least as high as
the general pediatric population. Most studies found that
children with JIA had significantly higher levels of anxiety
and/or depressive symptoms than healthy children.23,33,47,48
The wide range in symptom prevalence among studies may
be attributed to differences in populations, differences in
definition or measurement of symptomatology, and differ-
ences in methods used to obtain information about patients’
anxiety and depression symptoms. In contrast to the earlier
literature that depended heavily on parent-reported scales
for depression and anxiety,8 the reviewed studies mostly
relied on patient self-reported symptom scales. Lal et al
assessed the level of agreement between adolescents with
JIA and their caregivers with regards to mental health and
well-being. Adolescents who reported more depressive
symptoms were more likely to disagree with their parents
about depressive symptoms.26 Other reviewed studies also
found discrepancies between patient self-reported and par-
ent-reported symptoms of depression/anxiety through
screening tools such as the CBCL.54,55 In pre-adolescent
children, there is likely a role for both patient self-report
and parent-proxy reports to build a complete picture of a
child’s mental health.
Likewise, it is still unclear how disease duration may
impact the risk of anxiety and depression. Butler et al
hypothesized that symptoms would improve after the
initial adjustment to illness and found a slight decrease
in symptoms at 6 months of follow-up.29 This is supported
by an earlier study that found that adolescents with lower
symptoms of anxiety and depression tended to have longer
duration of disease.56 El-Najjar et al found the opposite
correlation between disease duration and depressive
symptoms.37 It is possible that longer disease durations
are associated with increased damage and changes to func-
tion that may increase the risk of developing symptoms of
depression. This relationship has been seen with depres-
sion in diabetes.57,58
Unfortunately, most studies did not perform a separate
analysis of mental health symptoms by JIA subtype due to
small sample sizes. In one study, polyarticular JIA patients
were found to have significantly higher depressive scores
than both oligoarticular and ERA patients.46 Similarly, an
older study reported that adults with RF-negative polyarti-
cular JIA have particularly high rates of depressive symp-
toms in comparison to adults with other subtypes.59 It is
possible that polyarticular JIA patients are at an increased
risk for depression compared to other subtypes because
they commonly suffer from higher active joint counts and
higher disease activity which may impair overall function
and lead to lower quality of life. On the other hand, El-
Najjar et al did not find any significant differences in
depressive scores between oligoarticular, polyarticular,
systemic, and ERA patients; though in this study, all of
the patients scored above the cutoff for significant depres-
sive symptoms.37 No included studies examined anxiety
symptoms and JIA subtype.
Only a quarter of the studies investigated relationships
between other JIA disease characteristics and mental
health symptoms. Disease characteristics were assessed
in various ways, making comparisons between studies
difficult. Most, but not all, of these studies found a positive
correlation between higher disease activity and depression/
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anxiety symptoms.37,43,46 Of note, some of the earlier
literature conflicts with these findings.55
The impact of JIA treatment on symptoms of depres-
sion and anxiety was rarely approached in the reviewed
studies; however, our search approach was not wide
enough to include studies of treatments that reported
symptoms of depression and anxiety outside of the main
findings highlighted in their abstracts. This is an area
deserving of study, especially considering that systemic
and brain inflammation have been implicated in psychia-
tric conditions60 such as depression, and anti-tumor necro-
sis factor (anti-TNF) therapy was recently studied as a
potential treatment for refractory depression with mixed
results.61 In a randomized controlled trial of infliximab for
refractory depression, infliximab did not improve depres-
sion scores compared to placebo in the overall study
population; however, in an exploratory analysis of patients
with elevated baseline inflammatory markers, there was a
decrease in depression symptoms with infliximab com-
pared to placebo.61 In contrast, depression and anxiety
have been reported in small numbers in clinical trials of
TNF-inhibitors and other treatments used for arthritis in
patients with JIA.62–64 Hider et al specifically evaluated
depression in adults with rheumatoid arthritis on anti-TNF
therapy. Although 48% of the patients had depression at
baseline, after a year of anti-TNF therapy the proportion of
patients with persistent depression fell to 15% and only
6% of the patients on anti-TNF therapy developed new-
onset depression. Therefore, they concluded that anti-TNF
therapy is not likely to adversely affect mood.65
Because the vast majority of studies reviewed were
cross-sectional, the direction of the relationship between
disease activity and mental health symptoms is still poorly
described. It is plausible that depressive symptoms may
lead to worse disease activity, especially if patients
become non-adherent with medical care as a result of
their mental health symptoms. In other disease processes,
including childhood-onset lupus, medication adherence
has been linked to depressive symptoms.66 But it is
equally plausible that worse disease activity is leading to
the development of depressive symptoms. Although most
studies were cross-sectional, three studies in adult JIA
patients were reviewed to address long-term consequences
of JIA. Two were designed to specifically answer the
question of how JIA patients fared emotionally as adults
and found that 30–40% of the adults with JIA had symp-
toms of anxiety or depression.43,44 The other study by
Raab et al found that adults with JIA had a lower rate of
lifetime prevalence of depression compared to a commu-
nity sample of age-/gender-matched controls.42 However,
the prior literature also indicates that adults with JIA may
have worse anxiety and depression than their healthy
peers.59,67,68 Therefore, significant psychopathology can
impact patients into adulthood and may influence their
emotional, social, and overall quality of life. This is simi-
lar to what has been reported in children with other
chronic diseases such as chronic kidney disease and epi-
lepsy along with many others.4–6,69,70 However, in contrast
to many other chronic conditions, JIA is characterized by
unpredictable flares amidst periods of quiescence and
often preceded by significant delays in diagnosis, all of
which may further contribute to the development of anxi-
ety and depression.
Although there were two articles that did not find any
significant relationship between pain and depression or
anxiety symptoms, most of the articles did find that pain
was significantly correlated with symptoms.24,31,37,45,46,50
This is consistent with earlier literature.18 Older literature
in JIA reported mixed results with many studies finding a
correlation between pain and depression/anxiety symp-
toms, while some reported weak or no significant
association.12,71 Hanns et al even found that baseline
depressive symptoms predicted worse pain and disability
up to 4 years later.46 Overall, most of the literature points
to an association between pain and psychological symp-
toms, though much of it does not account for all the
potential confounders such as disease severity, activity,
disability, and patient demographics.
Physical disability appears to be correlated to mental
health symptoms, as well. In two studies, the CHAQ was
found to correlate with depressive symptom scores.31,37
An earlier cluster analysis of JIA patients by age, anxiety,
and depression symptoms found that adolescents with JIA
who were more symptomatic of both depression and anxi-
ety also had higher rates of pain, disability, and active joint
counts.56 Other older literature has reported moderate
associations between disability and depression/anxiety
symptoms, both in children and adults with JIA.59,72
Difficulties in functioning and overall ability to complete
activities of daily living may cause children with JIA to
feel different than their healthy peers, which may ulti-
mately affect their mood. Additionally, any physical
changes or difficulties that are apparent to their peers
could lead to bullying which is tied to the development
of mental health symptoms.73,74
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The overall quality of life was worse or impaired in JIA
patients with higher depressive scores.31,34,35,39 Sleep quality
of life was also impacted with most JIA patients reporting
some sleep disturbance which correlated with anxiety and
depressive symptoms, and mood moderated the relationship
between poor sleep and pain.28,45 This may create a vicious
cycle. Pain can interfere with sleep, sleep disturbances can
worsen pain, worse pain can lead to feelings of depression,
depression can impact sleep and exacerbate pain, and poor
sleep can worsen depression further. School quality of life
was also impacted by depression, an association that can be
explained by how people with depression struggle with par-
ticipating and performing daily activities.38 Prior studies
have documented the relationship between depressive symp-
toms and school impairments in other chronic patient popu-
lations such as chronic pain.75
Building off the previous literature that indicated that
family and parental characteristics and adjustment are
associated with child adaptation to illness,76 several of
the recent studies we reviewed addressed the interconnec-
tivity between family and patient mental health in families
affected by JIA. Many of these studies found that parents
of children with JIA had clinically significant depressive
or anxious symptoms, and that symptoms of depression
and anxiety may be worse in family members of children
with active disease.24,32,40 In addition, more parent daily
stress with little stress relief also predicted higher depres-
sive symptoms in their children with JIA.25 Vuroimaa et al
found that child and parent depressive and anxious symp-
toms correlated with each other and the child’s pain was
associated with the parent’s depressive symptoms.24 This
is likely because of shared environmental and genetic
predispositions as well as the possibility that one family
member’s mental health symptoms are influencing the
other’s.77–79 With evidence of significant family psycho-
pathology and psychological distress, it is likely beneficial
for the child’s mental health to address the parent’s mental
health, too.
Study Limitations
Limitations to this review include the challenges of devel-
oping a screening process for a broad topic that is dis-
cussed with multiple different terms. We may have missed
important studies that had keywords related to emotional
or mental health and addressed internalized symptoms
such as depression and anxiety, without specifically listing
them as keywords. Furthermore, we missed articles by
limiting our scope to English-language publications.
Knowledge gained by our review was also limited by
the limitations of the individual studies. Most of the stu-
dies that were included were cross-sectional studies, so
symptoms of depression/anxiety were evaluated only at
one particular time point. Therefore, trends in symptoms
over time could not be evaluated to see if they persisted,
worsened, or improved. Consequently, patients who were
experiencing symptoms of anxiety/depression outside of
the time frame they participated in the study would have
been missed. Studies, especially cross-sectional, may
introduce non-response bias in which the responses of
the people who chose to participate may differ from
those who chose to not participate. This may be particu-
larly true for studies involving mental health, where
stigma still exists around the topic in some cultures.
Lastly, cross-sectional studies allow you to make conclu-
sions about possible associations, but not about causation.
Many of the studies had small sample sizes which can
impact the significance and generalizability of the results.
Although, most studies were still able to report on statis-
tically significant differences comparing JIA to controls.
However, small sample sizes did not provide enough
power for most of the studies to complete any analysis
about how JIA disease characteristics, medications, or
subtypes may be correlated with mental health symptoms.
Disease activity was assessed and analyzed with regards to
mental health symptoms by varying measures of disease
activity making it hard to make comparisons and overall
conclusions. Furthermore, some studies only included
patients who were in remission or had low/mild disease
activity and others excluded patients with known psychia-
tric diseases. This can lead to potential selection bias,
challenging us to compare these and synthesize the dis-
parate observations into a singular understanding of how
anxiety and depression impact youth with JIA.
Additionally, few studies reported patient sociodemo-
graphics, and US and European countries that reported
race/ethnicity of patients still included few racial and
ethnic minorities again limiting generalizability.24–29
Conclusion
Recent literature indicates that youth with JIA experience
clinically significant symptoms of anxiety and depression
similar to youth with other chronic diseases and likely at
higher rates than healthy children. These studies have
added to the body of literature that address JIA specifi-
cally, as opposed to general juvenile rheumatic diseases
and help to reinforce the need and importance of mental
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health screening and surveillance specifically in children
with JIA. The reviewed studies show an increasing inclu-
sion of work worldwide, even with our limitation in scope
to English-language journals. Across diverse geo-cultural
backgrounds, it is clear that mental health symptoms are
an important part of the experience of JIA and something
to which pediatric rheumatology providers must attend.
However, many of the challenges of the early literature
still beleaguer the literature of the last ten years. It is likely
that large populations of youth with JIA are still not well
represented in the literature and this inhibits our under-
standing of how mental health symptoms impact all
patients and which patients are at greatest risk. Disease
activity and pain were found in a few articles to correlate
with worse depressive and anxiety symptoms; however,
the majority of the articles did not perform an analysis of
the associations between JIA disease characteristics or
subtype with mental health symptoms. More studies are
needed to better understand the complex nature of how
parents’ and other family members’ emotional health
impacts the affected child’s and vice versa. Furthermore,
the studies are almost uniformly cross-sectional studies
that still leave unanswered questions about how patients
progress over time and how the unpredictable and undu-
lating course of JIA disease activity impacts mood and
mental health.
As the importance of mental health symptoms to patients
and families is continually raised by the arthritis patient
community, measurements of these symptoms should be
incorporated in the large international longitudinal pediatric
rheumatology registries. These studies, which may benefit
from a coupling of biospecimen banks, will enhance our
understanding of how JIA disease and mental health symp-
toms interplay over time, how they each impact one another,
and may help us understand whether mental health symp-
toms influence the pathophysiology of inflammatory arthritis
or vice versa. This information could provide evidence to
target mental health screening efforts, identify novel and
effective treatment pathways, and develop individualized
therapy plans for youth with JIA.
Though gaps persist in our knowledge of how depres-
sion and anxiety influence specific disease factors in JIA,
the recent literature clearly points to the role that depres-
sion and anxiety symptoms have on quality of life, both
for the child with JIA and their family. Pediatric rheuma-
tologists need to consider addressing these symptoms if
they wish to promote improved quality of life for their
patients.
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